Insider · CIK 0001876996

Waltermire Robert E.

Reports to the SEC for 1 company · WEST CONSHOHOCKEN, PA

sec.gov

Transactions

Companies

Filings

CIK

0001876996

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2025-03-05	MDGLMADRIGAL PHARMACEUTICALS, INC.S Sale	Senior VP, Chief Pharma Dev.	SSale	−1,077 sh	$342.90	−$369K	9,841
2025-03-05	MDGLMADRIGAL PHARMACEUTICALS, INC.S Sale	Senior VP, Chief Pharma Dev.	SSale	−4,701 sh	$343.85	−$1.62M	5,140
2025-03-05	MDGLMADRIGAL PHARMACEUTICALS, INC.S Sale	Senior VP, Chief Pharma Dev.	SSale	−1,412 sh	$344.76	−$487K	3,728
2025-03-05	MDGLMADRIGAL PHARMACEUTICALS, INC.A Award	Senior VP, Chief Pharma Dev.	AAward	+2,061 sh	—	—	5,789
2025-03-05	MDGLMADRIGAL PHARMACEUTICALS, INC.M Exercise/Conversion	Senior VP, Chief Pharma Dev.	MExercise/Conversion	+6,825 sh	$87.92	+$600K	10,553
2025-03-05	MDGLMADRIGAL PHARMACEUTICALS, INC.M Exercise/Conversion	Senior VP, Chief Pharma Dev.	MExercise/Conversion	+7,288 sh	$87.09	+$635K	17,841
2025-03-05	MDGLMADRIGAL PHARMACEUTICALS, INC.S Sale	Senior VP, Chief Pharma Dev.	SSale	−900 sh	$335.15	−$302K	16,941
2025-03-05	MDGLMADRIGAL PHARMACEUTICALS, INC.S Sale	Senior VP, Chief Pharma Dev.	SSale	−1,777 sh	$336.78	−$598K	15,164
2025-03-05	MDGLMADRIGAL PHARMACEUTICALS, INC.S Sale	Senior VP, Chief Pharma Dev.	SSale	−1,146 sh	$338.09	−$387K	14,018
2025-03-05	MDGLMADRIGAL PHARMACEUTICALS, INC.S Sale	Senior VP, Chief Pharma Dev.	SSale	−400 sh	$339.68	−$136K	13,618
2025-03-05	MDGLMADRIGAL PHARMACEUTICALS, INC.S Sale	Senior VP, Chief Pharma Dev.	SSale	−1,657 sh	$340.75	−$565K	11,961
2025-03-05	MDGLMADRIGAL PHARMACEUTICALS, INC.S Sale	Senior VP, Chief Pharma Dev.	SSale	−1,043 sh	$341.84	−$357K	10,918
2025-03-05	MDGLMADRIGAL PHARMACEUTICALS, INC. · Stock Option (Right to Buy)M Exercise/Conversion	Senior VP, Chief Pharma Dev.	MExercise/Conversion	−6,825 sh	—	—	4,375
2025-03-05	MDGLMADRIGAL PHARMACEUTICALS, INC. · Stock Option (Right to Buy)M Exercise/Conversion	Senior VP, Chief Pharma Dev.	MExercise/Conversion	−7,288 sh	—	—	3,062
2025-03-05	MDGLMADRIGAL PHARMACEUTICALS, INC. · Stock Option (Right to Buy)A Award	Senior VP, Chief Pharma Dev.	AAward	+1,157 sh	—	—	1,157
2025-02-28	MDGLMADRIGAL PHARMACEUTICALS, INC.S Sale	Senior VP, Chief Pharma Dev.	SSale	−1,052 sh	$340.99	−$359K	3,903
2025-02-28	MDGLMADRIGAL PHARMACEUTICALS, INC.S Sale	Senior VP, Chief Pharma Dev.	SSale	−175 sh	$341.55	−$59.8K	3,728
2025-01-24	MDGLMADRIGAL PHARMACEUTICALS, INC.S Sale	Senior VP, Chief Pharma Dev.	SSale	−103 sh	$335.24	−$34.5K	4,955
2025-01-17	MDGLMADRIGAL PHARMACEUTICALS, INC.S Sale	Senior VP, Chief Pharma Dev.	SSale	−442 sh	$273.41	−$121K	5,058
2024-06-14	MDGLMADRIGAL PHARMACEUTICALS, INC.M Exercise/Conversion	Senior VP, Chief Pharma Dev.	MExercise/Conversion	+1,900 sh	$87.09	+$165K	7,400
2024-06-14	MDGLMADRIGAL PHARMACEUTICALS, INC.S Sale	Senior VP, Chief Pharma Dev.	SSale	−1,900 sh	$280.00	−$532K	5,500
2024-06-14	MDGLMADRIGAL PHARMACEUTICALS, INC. · Stock Option (Right to Buy)M Exercise/Conversion	Senior VP, Chief Pharma Dev.	MExercise/Conversion	−1,900 sh	—	—	10,350
2024-06-12	MDGLMADRIGAL PHARMACEUTICALS, INC.M Exercise/Conversion	Senior VP, Chief Pharma Dev.	MExercise/Conversion	+2,000 sh	$87.92	+$176K	7,500
2024-06-12	MDGLMADRIGAL PHARMACEUTICALS, INC.S Sale	Senior VP, Chief Pharma Dev.	SSale	−2,000 sh	$285.00	−$570K	5,500
2024-06-12	MDGLMADRIGAL PHARMACEUTICALS, INC. · Stock Option (Right to Buy)M Exercise/Conversion	Senior VP, Chief Pharma Dev.	MExercise/Conversion	−2,000 sh	—	—	15,200
2024-05-21	MDGLMADRIGAL PHARMACEUTICALS, INC.S Sale	Senior VP, Chief Pharma Dev.	SSale	−1,036 sh	$231.34	−$240K	5,500
2024-01-23	MDGLMADRIGAL PHARMACEUTICALS, INC.A Award	Senior VP, Chief Pharma Dev.	AAward	+1,419 sh	—	—	6,536
2024-01-23	MDGLMADRIGAL PHARMACEUTICALS, INC. · Stock Option (Right to Buy)A Award	Senior VP, Chief Pharma Dev.	AAward	+2,138 sh	—	—	2,138
2024-01-23	MDGLMADRIGAL PHARMACEUTICALS, INC. · Market Stock UnitA Award	Senior VP, Chief Pharma Dev.	AAward	+1,419 sh	—	—	1,419
2024-01-16	MDGLMADRIGAL PHARMACEUTICALS, INC.F Tax Payment	Senior VP, Chief Pharma Dev.	FTax Payment	−550 sh	$243.92	−$134K	5,117
2023-12-15	MDGLMADRIGAL PHARMACEUTICALS, INC.M Exercise/Conversion	Senior VP, Chief Pharma Dev.	MExercise/Conversion	+2,000 sh	$87.92	+$176K	7,667
2023-12-15	MDGLMADRIGAL PHARMACEUTICALS, INC.S Sale	Senior VP, Chief Pharma Dev.	SSale	−1,000 sh	$236.00	−$236K	6,667
2023-12-15	MDGLMADRIGAL PHARMACEUTICALS, INC.S Sale	Senior VP, Chief Pharma Dev.	SSale	−1,000 sh	$241.00	−$241K	5,667
2023-12-15	MDGLMADRIGAL PHARMACEUTICALS, INC. · Stock Option (Right to Buy)M Exercise/Conversion	Senior VP, Chief Pharma Dev.	MExercise/Conversion	−2,000 sh	—	—	17,200
2023-12-14	MDGLMADRIGAL PHARMACEUTICALS, INC.M Exercise/Conversion	Senior VP, Chief Pharma Dev.	MExercise/Conversion	+2,000 sh	$87.92	+$176K	7,667
2023-12-14	MDGLMADRIGAL PHARMACEUTICALS, INC.S Sale	Senior VP, Chief Pharma Dev.	SSale	−1,000 sh	$233.00	−$233K	6,667
2023-12-14	MDGLMADRIGAL PHARMACEUTICALS, INC.S Sale	Senior VP, Chief Pharma Dev.	SSale	−1,000 sh	$232.00	−$232K	5,667
2023-12-14	MDGLMADRIGAL PHARMACEUTICALS, INC. · Stock Option (Right to Buy)M Exercise/Conversion	Senior VP, Chief Pharma Dev.	MExercise/Conversion	−2,000 sh	—	—	19,200
2023-12-13	MDGLMADRIGAL PHARMACEUTICALS, INC.M Exercise/Conversion	Senior VP, Chief Pharma Dev.	MExercise/Conversion	+2,500 sh	$87.92	+$220K	8,167
2023-12-13	MDGLMADRIGAL PHARMACEUTICALS, INC.S Sale	Senior VP, Chief Pharma Dev.	SSale	−1,500 sh	$225.00	−$338K	6,667
2023-12-13	MDGLMADRIGAL PHARMACEUTICALS, INC.S Sale	Senior VP, Chief Pharma Dev.	SSale	−1,000 sh	$226.00	−$226K	5,667
2023-12-13	MDGLMADRIGAL PHARMACEUTICALS, INC. · Stock Option (Right to Buy)M Exercise/Conversion	Senior VP, Chief Pharma Dev.	MExercise/Conversion	−2,500 sh	—	—	21,200
2023-12-12	MDGLMADRIGAL PHARMACEUTICALS, INC.M Exercise/Conversion	Senior VP, Chief Pharma Dev.	MExercise/Conversion	+1,300 sh	$87.92	+$114K	6,967
2023-12-12	MDGLMADRIGAL PHARMACEUTICALS, INC.S Sale	Senior VP, Chief Pharma Dev.	SSale	−500 sh	$216.00	−$108K	6,467
2023-12-12	MDGLMADRIGAL PHARMACEUTICALS, INC.S Sale	Senior VP, Chief Pharma Dev.	SSale	−800 sh	$219.00	−$175K	5,667
2023-12-12	MDGLMADRIGAL PHARMACEUTICALS, INC. · Stock Option (Right to Buy)M Exercise/Conversion	Senior VP, Chief Pharma Dev.	MExercise/Conversion	−1,300 sh	—	—	23,700
2023-03-01	MDGLMADRIGAL PHARMACEUTICALS, INC.M Exercise/Conversion	Senior VP, Chief Pharma Dev.	MExercise/Conversion	+5,000 sh	$87.92	+$440K	10,667
2023-03-01	MDGLMADRIGAL PHARMACEUTICALS, INC.S Sale	Senior VP, Chief Pharma Dev.	SSale	−1,928 sh	$273.44	−$527K	8,739
2023-03-01	MDGLMADRIGAL PHARMACEUTICALS, INC.S Sale	Senior VP, Chief Pharma Dev.	SSale	−1,672 sh	$274.57	−$459K	7,067
2023-03-01	MDGLMADRIGAL PHARMACEUTICALS, INC.S Sale	Senior VP, Chief Pharma Dev.	SSale	−1,300 sh	$275.53	−$358K	5,767

Recent filings

Accepted (ET)
Mar 74
Waltermire Robert E.0001628280-25-011405
SEC(opens sec.gov)
Mar 44
Waltermire Robert E.0001628280-25-010224
SEC(opens sec.gov)
Jan 274
Waltermire Robert E.0001628280-25-002655
SEC(opens sec.gov)
Jan 174
Waltermire Robert E.0001628280-25-001900
SEC(opens sec.gov)
Jun 184
Waltermire Robert E.0000950170-24-075221
SEC(opens sec.gov)

Companies

MADRIGAL PHARMACEUTICALS, INC.Senior VP, Chief Pharma Dev.MDGL

Address

C/O MADRIGAL PHARMACEUTICALS, INC. 200 BARR HARBOR DRIVE, SUITE 200

WEST CONSHOHOCKEN, PA, 19428